US Patent Issued to NantCell on April 29 for "Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses" (California Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,285,480, issued on April 29, was assigned to NantCell Inc. (Culver City, Calif.).

"Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses" was invented by Adrian Rice (Culver City, Calif.) and Mohit Verma (Culver City, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are methods for inducing immunity against a severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV2) in a patient in need thereof. The method comprises administering a vaccine composition comprising a self-adjuvanted SARS-CoV2 Spike (S) RNA-based vaccine (AAHI-SC2), fo...